{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T19:19:32Z","timestamp":1774984772784,"version":"3.50.1"},"reference-count":18,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T00:00:00Z","timestamp":1720915200000},"content-version":"unspecified","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2024,7,3]]},"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The Assessment of SpondyloArthritis international Society-European Alliance of Associations for Rheumatology recommendations for axial spondyloarthritis (axSpA) management include patient assessment for biological disease-modifying antirheumatic drug (bDMARD) treatment response after at least 12 weeks of treatment. The current treat-to-target strategy for axSpA is to achieve inactive disease (ID; Axial Spondyloarthritis Disease Activity Score (ASDAS) &lt;1.3) or at least low disease activity (LDA; 1.3\u2264ASDAS&lt;2.1).<\/jats:p>\n                  <jats:p>To investigate the association between treatment response at week 12 and\/or week 24 and attainment of the ASDAS&lt;2.1 treat-to-target recommendation at week 52 in bDMARD-na\u00efve patients with radiographic (r-)axSpA treated with ixekizumab (IXE).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This post hoc analysis included patients randomly assigned to IXE 80\u2009mg every 4 weeks from COAST-V (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02696785\">NCT02696785<\/jats:ext-link>), a phase 3 trial in bDMARD-na\u00efve patients with r-axSpA. The proportion of patients who achieved ASDAS&lt;2.1 at week 52 was measured among those who attained or not clinically important improvement (CII, \u2206ASDAS\u22651.1) response, and among those with ID, LDA and high or very high disease activity at week 12 and\/or week 24. Non-response was assumed for missing data.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Amongst 81 patients, 47 (58.0%) achieved ASDAS CII at week 12, with 70.2% (n=33) achieving ASDAS&lt;2.1 at week 52. At week 24, 52 (64.2%) patients achieved ASDAS CII, with 71.2% (n=37) achieving ASDAS&lt;2.1 at week 52. Of the 24 patients who did not achieve ASDAS CII at either week 12 or week 24, 5 (20.8%) achieved ASDAS&lt;2.1 at week 52.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This analysis reinforces the current recommendation that continuing treatment in those achieving ASDAS CII at week 12 and\/or week 24 increases the likelihood of obtaining ID\/LDA at week 52.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02696785\">NCT02696785<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2024-004429","type":"journal-article","created":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T10:45:14Z","timestamp":1720953914000},"page":"e004429","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Early clinical response associates with long-term outcomes with ixekizumab in radiographic axial spondyloarthritis"],"prefix":"10.1136","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct02696785","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02696785","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02696785","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8899-9087","authenticated-orcid":false,"given":"Sofia","family":"Ramiro","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands"},{"name":"Department of Rheumatology, Zuyderland Medical Centre, Heerlen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9dric","family":"Lukas","sequence":"additional","affiliation":[{"name":"University Hospital Centre of Montpellier, Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis","family":"Bessette","sequence":"additional","affiliation":[{"name":"Department of Medicine, Laval University, Quebec, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pendleton","family":"Wickersham","sequence":"additional","affiliation":[{"name":"Arthritis Associates, San Antonio, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tommaso","family":"Panni","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Bolce","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soyi","family":"Liu-Leage","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boris","family":"Janos","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6326-1764","authenticated-orcid":false,"given":"Michael J","family":"Nissen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Geneva University Hospitals, Geneve, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8285-1700","authenticated-orcid":false,"given":"James Cheng-\u00adChung","family":"Wei","sequence":"additional","affiliation":[{"name":"Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan"},{"name":"Department of Nursing, Chung Shan Medical University, Taichung, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,7,14]]},"reference":[{"key":"2025090313431023000_10.3.e004429.1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221035"},{"key":"2025090313431023000_10.3.e004429.2","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/acr.21621","article-title":"Prevalence of axial Spondylarthritis in the United States: estimates from a cross-sectional survey","volume":"64","author":"Reveille","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090313431023000_10.3.e004429.3","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/acr.21994","article-title":"Prevalence of axial Spondyloarthritis in United States rheumatology practices: assessment of Spondyloarthritis International society criteria versus rheumatology expert clinical diagnosis","volume":"65","author":"Strand","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090313431023000_10.3.e004429.4","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001108","article-title":"Characteristics and burden of disease in patients with radiographic and non-radiographic axial Spondyloarthritis: a comparison by systematic literature review and meta-analysis","volume":"5","author":"L\u00f3pez-Medina","year":"2019","journal-title":"RMD Open"},{"key":"2025090313431023000_10.3.e004429.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215707"},{"key":"2025090313431023000_10.3.e004429.6","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-225185"},{"key":"2025090313431023000_10.3.e004429.7","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223296"},{"key":"2025090313431023000_10.3.e004429.8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219585"},{"key":"2025090313431023000_10.3.e004429.9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211734"},{"key":"2025090313431023000_10.3.e004429.10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213184"},{"key":"2025090313431023000_10.3.e004429.11","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/acr.23092","article-title":"Early disease activity or clinical response as predictors of long-term outcomes with Certolizumab Pegol in axial Spondyloarthritis or Psoriatic arthritis","volume":"69","author":"van der Heijde","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090313431023000_10.3.e004429.12","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-021-02650-4","article-title":"Predictors of long-term clinical response in patients with non-radiographic axial Spondyloarthritis receiving Certolizumab Pegol","volume":"23","author":"Maksymowych","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"2025090313431023000_10.3.e004429.13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31946-9"},{"key":"2025090313431023000_10.3.e004429.14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216118"},{"key":"2025090313431023000_10.3.e004429.15","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.221022"},{"key":"2025090313431023000_10.3.e004429.16","doi-asserted-by":"crossref","first-page":"152078","DOI":"10.1016\/j.semarthrit.2022.152078","article-title":"Predictors of remission in people with axial Spondyloarthritis: a systematic literature review","volume":"56","author":"Pinto","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"2025090313431023000_10.3.e004429.17","doi-asserted-by":"crossref","DOI":"10.1186\/ar3369","article-title":"Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in Ankylosing Spondylitis: a prospective longitudinal observational cohort study","volume":"13","author":"Arends","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"2025090313431023000_10.3.e004429.18","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e32835257c5"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2024-004429","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:43:21Z","timestamp":1756932201000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2024-004429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":18,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,7,14]]},"published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1136\/rmdopen-2024-004429"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2024-004429","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]}}}